Company news

Promis Neurosciences Inc. (NASDAQ:PMN) news

Promis Neurosciences Inc. news releases on 6ix. Latest, Oct 6, 2026: ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana…

Promis Neurosciences Inc. (NASDAQ:PMN) news

Press releases & updates

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in June

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

ProMIS Neurosciences Announces Reverse Stock Split

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April